Fig. 4

DVL3 regulated CSLCs characteristics and multidrug resistance in CRC cells. A, B The expressions of DVL3, CD44, CD133, SOX2 and c-Myc in tumorspheres and adherent CRC cells (HCT-8 and SW620) were compared by Western blotting. C–F CCK8 assay was used to check the drug sensitivities of tumorspheres and adherent CRC cells treated with VCR or L-OHP for 48 h. The IC50 values of drugs were calculated from cell survival curves using the Bliss method. G Tumorsphere assay was employed to determine the ability of sphere formation in CRC cells transfected with LV-con or LV-DVL3, H and in CRC cells transfected with LV-shNC or LV-shDVL3. I–P CRC cells were transfected with pcDNA3.1, pcDNA3.1-DVL3, shNC or shDVL3 for 24 h, followed by treatment with VCR or L-OHP for additional 48 h. And then, the drug sensitivities of CRC cells were examined by CCK8 assay, and the IC50 values of drugs were calculated from cell survival curves using the Bliss method. Western blotting presented the expressions of CD44, CD133, SOX2 and c-Myc in CRC cells transfected with pcDNA3.1 or pcDNA3.1-DVL3 (Q, R), and shNC or shDVL3 (S, T) for 72 h. *P ≤ 0.05